Partners Roberto Pary and Lidia Rossi, along with lawyers Pedro Porcaro, Renzo Lima, and Juliana Rodrigues, advised EMS on the acquisition of Fresenius Kabi’s injectable generics manufacturing plant and R&D center in Anápolis, Brazil.
The deal includes the site, its warehouse, and transfer of staff, and is subject to customary closing conditions, including approval by CADE.
The transaction marks EMS’s reentry into the Brazilian injectables market and is expected to generate BRL 140 million in annual revenue. It also includes the expansion of production capacity and plans for a new facility in São Paulo.
Read the full article here.
